Seth S Martin1, Kamil F Faridi1, Parag H Joshi1, Michael J Blaha1, Krishnaji R Kulkarni2, Arif A Khokhar3, Thomas M Maddox4,5, Edward P Havranek5, Peter P Toth1,6,7, Fengming Tang8, John A Spertus8, Steven R Jones1. 1. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland. 2. Atherotech Diagnostics Laboratory, Birmingham, Alabama. 3. Northwest London Hospitals NHS Trust, London, United Kingdom. 4. VA Eastern Colorado Health Care System, Denver, Colorado. 5. University of Colorado School of Medicine, Aurora, Colorado. 6. Department of Preventive Cardiology, CGH Medical Center, Sterling, Illinois. 7. University of Illinois School of Medicine, Peoria, Illinois. 8. Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri.
Abstract
BACKGROUND: Remnants are partially hydrolyzed, triglyceride-rich lipoproteins that, like other apolipoprotein B-containing lipoproteins, are atherogenic. Prior observational studies suggest paradoxically better outcomes in hypercholesterolemic patients who sustain an acute myocardial infarction (AMI), one of several known recurrent risk paradoxes. To date, the association of directly measured remnant lipoprotein cholesterol (RLP-C) with survival after an AMI has not been examined. HYPOTHESIS: Higher RLP-C levels may be paradoxically associated with lower mortality. METHODS: We examined 2465 AMI survivors in a prospective, 24-center US study of AMI outcomes. Lipoprotein cholesterol subfractions were directly measured by ultracentrifugation. RLP-C was defined as intermediate-density lipoprotein cholesterol (IDL-C) + very-low-density lipoprotein cholesterol subfraction 3 (VLDL3 -C). Given a linear relationship between RLP-C and mortality, we examined RLP-C by tertiles and continuously. Cox regression hazard ratios (HRs) were adjusted for the Global Registry of Acute Coronary Events (GRACE) score and 23 other covariates. RESULTS: Participants were age 58 ± 12 years (mean ± SD), and 68% were men. After 2 years of follow-up, 226 (9%) participants died. The mortality proportion was 12.4% in the lowest tertile of RLP-C (0-15 mg/dL), 8.5% in the middle tertile (16-23 mg/dL), and 6.8% in the highest tertile (24-120 mg/dL; P < 0.001). A 1-SD increase in RLP-C (11 mg/dL) predicted a 24% lower adjusted risk of 2-year mortality (HR: 0.76, 95% confidence interval [CI]: 0.64-0.91). Similar results were found for a 1-SD increase in IDL-C (HR per 8 mg/dL: 0.80, 95% CI: 0.67-0.96), VLDL3 -C (HR per 4 mg/dL: 0.74, 95% CI: 0.61-0.89), and very-low-density lipoprotein cholesterol (VLDL-C; HR per 8 mg/dL: 0.69, 95% CI: 0.55-0.85). CONCLUSIONS: Higher RLP-C levels were associated with lower mortality 2 years after AMI despite rigorous adjustment for known confounders. Unknown protective factors or a lead-time bias likely explains the paradox.
BACKGROUND: Remnants are partially hydrolyzed, triglyceride-rich lipoproteins that, like other apolipoprotein B-containing lipoproteins, are atherogenic. Prior observational studies suggest paradoxically better outcomes in hypercholesterolemicpatients who sustain an acute myocardial infarction (AMI), one of several known recurrent risk paradoxes. To date, the association of directly measured remnant lipoprotein cholesterol (RLP-C) with survival after an AMI has not been examined. HYPOTHESIS: Higher RLP-C levels may be paradoxically associated with lower mortality. METHODS: We examined 2465 AMI survivors in a prospective, 24-center US study of AMI outcomes. Lipoprotein cholesterol subfractions were directly measured by ultracentrifugation. RLP-C was defined as intermediate-density lipoprotein cholesterol (IDL-C) + very-low-density lipoprotein cholesterol subfraction 3 (VLDL3 -C). Given a linear relationship between RLP-C and mortality, we examined RLP-C by tertiles and continuously. Cox regression hazard ratios (HRs) were adjusted for the Global Registry of Acute Coronary Events (GRACE) score and 23 other covariates. RESULTS:Participants were age 58 ± 12 years (mean ± SD), and 68% were men. After 2 years of follow-up, 226 (9%) participants died. The mortality proportion was 12.4% in the lowest tertile of RLP-C (0-15 mg/dL), 8.5% in the middle tertile (16-23 mg/dL), and 6.8% in the highest tertile (24-120 mg/dL; P < 0.001). A 1-SD increase in RLP-C (11 mg/dL) predicted a 24% lower adjusted risk of 2-year mortality (HR: 0.76, 95% confidence interval [CI]: 0.64-0.91). Similar results were found for a 1-SD increase in IDL-C (HR per 8 mg/dL: 0.80, 95% CI: 0.67-0.96), VLDL3 -C (HR per 4 mg/dL: 0.74, 95% CI: 0.61-0.89), and very-low-density lipoprotein cholesterol (VLDL-C; HR per 8 mg/dL: 0.69, 95% CI: 0.55-0.85). CONCLUSIONS: Higher RLP-C levels were associated with lower mortality 2 years after AMI despite rigorous adjustment for known confounders. Unknown protective factors or a lead-time bias likely explains the paradox.
Authors: E Boersma; K S Pieper; E W Steyerberg; R G Wilcox; W C Chang; K L Lee; K M Akkerhuis; R A Harrington; J W Deckers; P W Armstrong; A M Lincoff; R M Califf; E J Topol; M L Simoons Journal: Circulation Date: 2000-06-06 Impact factor: 29.690
Authors: Frederick A Spencer; Jeanna Allegrone; Robert J Goldberg; Joel M Gore; Keith A A Fox; Christopher B Granger; Rajendra H Mehta; David Brieger Journal: Ann Intern Med Date: 2004-06-01 Impact factor: 25.391
Authors: Stefania Lamon-Fava; David M Herrington; David M Reboussin; Michelle Sherman; Katalin V Horvath; L Adrienne Cupples; Charles White; Serkalem Demissie; Ernst J Schaefer; Bela F Asztalos Journal: Arterioscler Thromb Vasc Biol Date: 2008-01-03 Impact factor: 8.311
Authors: Tracy Y Wang; L Kristin Newby; Anita Y Chen; Jyotsna Mulgund; Matthew T Roe; Ali F Sonel; Deepak L Bhatt; Elizabeth R DeLong; E Magnus Ohman; W Brian Gibler; Eric D Peterson Journal: Clin Cardiol Date: 2009-09 Impact factor: 2.882
Authors: Christopher B Granger; Robert J Goldberg; Omar Dabbous; Karen S Pieper; Kim A Eagle; Christopher P Cannon; Frans Van De Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Keith A A Fox Journal: Arch Intern Med Date: 2003-10-27
Authors: Yashashwi Pokharel; Yuanyuan Tang; Bhaskar Bhardwaj; Krishna K Patel; Mohammed Qintar; James H O'Keefe; Krishnaji R Kulkarni; Peter H Jones; Seth S Martin; Salim S Virani; John A Spertus Journal: J Clin Lipidol Date: 2017-10-03 Impact factor: 4.766
Authors: Mohammed Yousufuddin; Paul Y Takahashi; Brittny Major; Eimad Ahmmad; Hossam Al-Zubi; Jessica Peters; Taylor Doyle; Kelsey Jensen; Ruaa Y Al Ward; Umesh Sharma; Ashok Seshadri; Zhen Wang; Vinaya Simha; M Hassan Murad Journal: BMJ Open Date: 2019-12-15 Impact factor: 2.692
Authors: Parag H Joshi; Arif A Khokhar; Joseph M Massaro; Seth T Lirette; Michael E Griswold; Seth S Martin; Michael J Blaha; Krishnaji R Kulkarni; Adolfo Correa; Ralph B D'Agostino; Steven R Jones; Peter P Toth Journal: J Am Heart Assoc Date: 2016-04-29 Impact factor: 5.501
Authors: Grzegorz M Kubiak; Magdalena Dobrolińska; Elżbieta Pociask; Wojciech Wańha; Paweł Gąsior; Grzegorz Smolka; Andrzej Ochała; Wojciech Wojakowski; Tomasz Roleder Journal: Postepy Kardiol Interwencyjnej Date: 2018-12-11 Impact factor: 1.426
Authors: Mohammed Yousufuddin; Ye Zhu; Ruaa Al Ward; Jessica Peters; Taylor Doyle; Kelsey L Jensen; Zhen Wang; Mohammad Hassan Murad Journal: Open Heart Date: 2020-03-17